ApoE polymorphism may determine low-density lipoprotein cholesterol level in association with obesity and metabolic syndrome in postmenopausal korean women

Yonsei Medical Journal

Volumn 52, Issue 3, 2011, Pages 429-434

  Lee, Duck Joo ^a   Kim, Kwang Min ^a   Kim, Bom Taeck ^a   Kim, Kyu Nam ^a   Joo, Nam Seok ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

ApoE polymorphism; LDL; Metabolic syndrome; Obesity

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; POSTMENOPAUSE; PREVALENCE; SOUTH KOREA;

AGED; APOLIPOPROTEINS E; CHOLESTEROL, LDL; FEMALE; HUMANS; MIDDLE AGED; OBESITY; POLYMORPHISM, GENETIC; POSTMENOPAUSE; REPUBLIC OF KOREA; SYNDROME;

EID: 79955640294     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2011.52.3.429     Document Type: Article

References (31)

1. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
2. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994;45:249-302.
3. Weisgraber KH, Rall SC Jr, Mahley RW. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981;256:9077-83.
4. Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933-49.
5. Garg A. Lipodystrophies. Am J Med 2000;108:143-52.
6. Haslam DW, James WP. Obesity. Lancet 2005;366:1197-209.
7. Zechner R, Moser R, Newman TC, Fried SK, Breslow JL. Apolipoprotein E gene expression in mouse 3T3-L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J Biol Chem 1991;266:10583-8.
8. Elosua R, Demissie S, Cupples LA, Meigs JB, Wilson PW, Schaefer EJ, et al. Obesity modulates the association among APOE genotype, insulin, and glucose in men. Obes Res 2003;11:1502-8.
9. Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. Am J Epidemiol 2006;164:342-8.
10. Feitosa MF, Rice T, North KE, Kraja A, Rankinen T, Leon AS, et al. Pleiotropic QTL on chromosome 19q13 for triglycerides and adiposity: the HERITAGE Family Study. Atherosclerosis 2006;185:426-32.
11. Wilson PW, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
12. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA 2007;298:1300-11.
13. Zintzaras E, Kitsios GD, Triposkiadis F, Lau J, Raman G. APOE gene polymorphisms and response to statin therapy. Pharmacogenomics J 2009;9:248-57.
14. Nieminen T, Kähönen M, Viiri LE, Grönroos P, Lehtimäki T. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics 2008;9:1475-86.
15. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
16. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.
17. The cutoff points of waist circumference for abdominal obesity. Korean Society for the Study of Obesity. 2006;15:1-9.
18. The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne: International Diabetes Institute; 2000 Feb. Sponsored by the Regional Office for the Western Pacific WPRO), World Health Organization, the International Association for the Study of Obesity, and the International Obesity Task Force.
19. Lamarche B, Lemieux I, Després JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25:199-211.
20. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. Circulation 1997;95:69-75.
21. Ho RC, Davy K, Davy B, Melby CL. Whole-body insulin sensitivity, low-density lipoprotein (LDL) particle size, and oxidized LDL in overweight, nondiabetic men. Metabolism 2002;51:1478-83.
22. Goff DC Jr, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study. Metabolism 2005;54:264-70.
23. Chiba T, Nakazawa T, Yui K, Kaneko E, Shimokado K. VLDL induces adipocyte differentiation in ApoE-dependent manner. Arterioscler Thromb Vasc Biol 2003;23:1423-9.
24. Huang ZH, Reardon CA, Mazzone T. Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes 2006;55:3394-402.
25. Gao J, Katagiri H, Ishigaki Y, Yamada T, Ogihara T, Imai J, et al. Involvement of apolipoprotein E in excess fat accumulation and insulin resistance. Diabetes 2007;56:24-33.
26. Sima A, Iordan A, Stancu C. Apolipoprotein E polymorphism--a risk factor for metabolic syndrome. Clin Chem Lab Med 2007;45:1149-53.
27. Knouff C, Hinsdale ME, Mezdour H, Altenburg MK, Watanabe M, Quarfordt SH, et al. Apo E structure determines VLDL clearance and atherosclerosis risk in mice. J Clin Invest 1999;103: 1579-86.
28. Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 2000;74:1008-16.
29. Lucic D, Huang ZH, Gu de S, Altenburg MK, Maeda N, Mazzone T. Regulation of macrophage apoE secretion and sterol efflux by the LDL receptor. J Lipid Res 2007;48:366-72.
30. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55-61.
31. Hu P, Qin YH, Jing CX, Lu L, Hu B, Du PF. Does the geographical gradient of ApoE4 allele exist in China? A systemic comparison among multiple Chinese populations. Mol Biol Rep 2011;38:489-94.